This study is looking at how the body processes a drug called quizartinib in people with severe hepatic impairment (liver problems). It will compare this to how healthy people process the drug. Participants will receive a single 30 mg dose of quizartinib. Researchers will measure how much of the drug is in your body over about a month to understand its pharmacokinetics (how the body absorbs, distributes, metabolizes, and excretes a drug). This helps determine if the drug needs to be given differently to people with liver issues. The study aims to enroll 12 participants between 18 and 75 years old, with a body mass index (BMI) between 18 and 37 kg/m2. The current recruitment status is unclear.

Study design

This is a clinical pharmacology study with two groups: people with severe liver impairment and healthy volunteers. It will involve about 12 participants.

What's involved

Participants will receive a single oral dose of quizartinib and have their blood levels of the drug measured from the day of the dose through Day 29.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for pharmacokinetic measurements from the day of the first dose through Day 29.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.